Fig. 3From: Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in JapanKaplan-Meier curves of progression free survival (PFS) in mRCC patients treated with sorafenib plus IFN-α. The median PFS was 10.1 months (95 % CI, 6.4 to 18.5)Back to article page